Trial Profile
SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Triamcinolone (Primary)
- Indications Retinal oedema; Retinal vein occlusion
- Focus Registrational; Therapeutic Use
- Acronyms SAPPHIRE
- Sponsors Clearside Biomedical
- 20 Dec 2021 The trial has been completed in Hungary, according to European Clinical Trials Database record.
- 11 Jan 2019 The trial has been discontinued in poland.
- 07 Jan 2019 Status changed from active, no longer recruiting to discontinued.